Pharmaceuticals, Biotechnology and Life Sciences
Aytu BioScience, a drugmaker focused on urology products, has increased gross product sales by 47% from the quarter ended September 30, 2016 to the quarter ended December 31, 2016, from $925,000 to $1,358,000, getting its first ever $1M-plus quarter sales.
Hybrigenics has given an update on the Phase II clinical study of inecalcitol in chronic myeloid leukemia (CML) administered in addition to imatinib, the reference inhibitor of BCR-ABL kinase used as standard of care for CML.
The Muscular Dystrophy Association said yesterday it welcomed news of the U.S. Food and Drug Administration’s decision to grant approval for deflazacort (Emflaza), developed by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.
The consumption levels are anticipated to rise exponentially over the forecast period. The companies and government organizations are working collaboratively to bridge the gap between supply and demand.
Forward Pharma has received $ 1.25 billion due to the settlement with Biogen’s subsidiaries, it made in January.
The U.S. Food and Drug Administration (FDA) has approved Marathon Pharmaceuticals’s Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness.
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
Ablynx will present additional data from the Phase IIb RA combination study of its anti-IL-6R Nanobody, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada).
Eli Lilly has welcomed Carolyn R. Bertozzi, Ph.D., as a new member, of its board, starting on February 10, 2017, joining two committees of the board.